The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts’ Proposal

Dyslipidaemia remains a major contributor to cardiovascular morbidity and mortality, despite the availability of effective lipid-lowering therapies and well-established European Society of Cardiology/European Atherosclerosis Society guidelines. In clinical practice, the implementation of these recommendations is often suboptimal, with persistent therapeutic inertia and fragmented decision-making processes. The CARDIOLIPID Plan is a proposed cardiovascular risk-centred implementation framework designed to support the practical application of guideline-based care. The model integrates two key components of clinical decision-making: comprehensive cardiovascular risk assessment (CARDIO) and personalised lipid-lowering intervention (LIPID), structured into a sequential and clinically applicable pathway. While the individual elements of the CARDIOLIPID Plan are derived from current evidence and guideline recommendations, their organisation within this framework reflects an interpretation by experts aimed at improving clarity, usability and clinical implementation. The model emphasises early and appropriate treatment intensification, reduction of therapeutic inertia and a holistic, patient-centred approach to cardiovascular risk management. The CARDIOLIPID Plan may serve as a practical tool to enhance the translation of evidence into clinical practice. However, as a conceptual and implementation-oriented framework, it requires validation in real-world settings to assess its impact on treatment outcomes and cardiovascular risk reduction.